Arialys Therapeutics

About

Arialys Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for autoimmune neuropsychiatric diseases. Founded in 2021 and emerging from stealth in 2023, the company has made significant strides in its therapeutic pipeline, supported by $58 million in seed funding. Arialys operates at the intersection of autoimmune neurology and psychiatry, addressing conditions where autoantibodies disrupt central nervous system function. The company's lead investigational therapy, ART5803, is designed to selectively neutralize pathogenic anti-NMDAR autoantibodies while preserving normal receptor function. Currently in Phase 1 clinical trials for anti-NMDAR encephalitis, dosing for this therapy began in October 2024. Arialys aims to target various autoimmune-driven neuropsychiatric conditions, including schizophrenia, dementia, and cognitive impairments related to stroke and cancer. Their innovative approach leverages structural analysis of autoantibody-receptor interactions to create therapies that block harmful effects without systemic immunosuppression.